ARVN (Arvinas Inc.) stock: $8.29, $542.1M market cap, $567.9M cash, -$25.5M EV, $668.2M fully diluted market cap. Next expected readout: Nov-26. Lead program: ARV-806 (KRAS G12D Mutation), Phase 2. Data from Fully Diluted's biotech stocks database.
Balance sheet
| Cash | $567.9M |
|---|
| Debt | $0.3M |
|---|
| Net cash | $567.6M |
|---|
| Enterprise value | -$25.5M |
|---|
| Basic shares | 65.3M shares |
|---|
| Fully diluted shares | 80.6M shares |
|---|
| Fully diluted market cap | $668.2M |
|---|
| Cash per share | $8.70 |
|---|
Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.
Price history
Loading ARVN daily closes…
Loading price history…
Upcoming catalysts
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|
| Jan 11 - Feb 22 | ARV-806 | Phase 2 | KRAS G12D Mutation; Advanced Solid Cancer | 2H 2026 |
| Jan 15 - Feb 26 | vepdegestrant | Phase 1 | Healthy Participants | — |
| Feb 10 - Mar 24 | Letrozole | Phase 3 | Breast Cancer | — |
| Feb 10 - Mar 24 | ARV-471 | Phase 2 | Breast Cancer | — |
| Feb 11 - Mar 25 | vepdegestrant | Phase 2 | Breast Cancer | — |
| May 5 - Jun 16 | ARV-471 | Phase 2 | Breast Cancer | — |
| Apr 12 - May 24 | ARV-393 | Phase 1 | Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL); Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL) | — |
| May 12 - Jun 23 | ARV-6723 | Phase 2 | Advanced Solid Tumor | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Full readout calendar →
Pipeline assets
Vepdegestrant (VEPPANU)
Approved · Active Modality: PROTAC degrader
Aliases ARV-471
Target ER
Partnerships Rigel Pharmaceuticals: exclusive global development, manufacturing and commercialization rights (May 2026); $70.0M upfront + $15.0M transition payment + up to $1.3B in milestones + royalties
Indications- ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer (Approved)
Status note FDA approved in Q2 2026 for ER+/HER2-, ESR1-mutated advanced/metastatic breast cancer after at least one line of endocrine therapy. Rigel responsible for US launch and holds global rights (may sublicense ex-US).
ARV-393
Phase 1 · Active Modality: PROTAC degrader
Target BCL6
Indications- Relapsed/refractory non-Hodgkin lymphoma (NHL) (Phase 1)
Status note In Phase 1 in relapsed/refractory NHL (early monotherapy cohorts; filing notes a higher-than-predicted proportion of T-cell lymphoma patients).
ARV-806
Stage not disclosed · Active Modality: IV PROTAC degrader
Target KRAS G12D
Indications- Pancreatic, colorectal, and non-small cell lung cancer with KRAS G12D mutation (Stage not disclosed)
Status note Investigational IV PROTAC KRAS G12D degrader. Filing groups it among current and/or future clinical trials; phase not explicitly stated. Company plans to seek an out-licensing agreement for additional clinical trials including dose expansion/combination.
ARV-102
Phase 1 · Active Modality: Oral PROTAC degrader
Target LRRK2
Indications- Parkinson's disease (PD) (Phase 1)
- Progressive supranuclear palsy (PSP) (Phase 1)
Status note Phase 1 in healthy volunteers (SAD/MAD completed) and in PD patients (SAD enrollment completed Q2 2025; multiple-dose cohort enrollment completed Q4 2025).
ARV-027
Stage not disclosed · Active Modality: PROTAC degrader
Target polyQ androgen receptor (skeletal muscle)
Indications- Spinal bulbar muscular atrophy (SBMA) (Stage not disclosed)
Status note Filing groups it among current and/or future clinical trials; phase not explicitly stated. Filing states the company believes it could become the first treatment option for SBMA (no therapies approved in the US or EU).
Luxdegalutamide
Stage not disclosed · Active Modality: PROTAC (small molecule)
Aliases ARV-766
Target Androgen receptor (AR)
Partnerships Novartis Pharma AG: worldwide development/manufacturing/commercialization license (Apr 2024); $150.0M upfront (paid May 2024) + up to $1.01B in milestones + royalties
Indications- Prostate cancer (Stage not disclosed)
Status note Second-generation PROTAC androgen receptor degrader; fully licensed to Novartis, which is responsible for worldwide clinical development and commercialization. Current clinical phase not stated in the 10-Q excerpts.
AR-V7 program
Preclinical · Active Modality: PROTAC (small molecule)
Target AR-V7 (androgen receptor splice variant)
Partnerships Novartis Pharma AG: AR-V7 program sold via asset purchase agreement (Apr 2024); Novartis holds all research/development/manufacturing/commercialization rights
Indications- not disclosed (Preclinical)
Status note Preclinical PROTAC degrader targeting the AR-V7 androgen receptor splice variant; asset sold to Novartis.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.